Supplementary Figure S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
<p>Figure S6 shows the FDA meta-analysis results for the overall survival endpoint across the three randomized studies (E1910, 20120215, AALL1331) and the literature study.</p>
Authors
- R. Angelo de Claro (ORCID: https://orcid.org/0000-0001-8362-1977)
- Shu Wang (ORCID: https://orcid.org/0000-0001-9813-6069)
- Jonathon Vallejo (ORCID: https://orcid.org/0000-0002-9700-4037)
- Xiling Jiang (ORCID: https://orcid.org/0009-0007-9775-240X)
- Donna Przepiorka (ORCID: https://orcid.org/0000-0002-4825-7775)
- Marc Robert Theoret (ORCID: https://orcid.org/0000-0003-4973-5297)
- Cara A. Rabik
- Ritu Chadda
Publication Details
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/1078-0432.30363072
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00